-
Journal of vascular and interventional radiology: JVIR 05/2013; 24(5):751. · 1.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: OBJECTIVE: The aim of the study was to evaluate prospectively the clinical impact of 2-(F)-fluoro-2-deoxy-D-glucose (F-FDG) PET/computed tomography (CT) on the pretreatment assessment of patients with colorectal lung metastasis before radiofrequency (RF) ablation. METHODS: The institutional review board approved this prospective study. The eligibility criteria for lung RF ablation were the presence of five or fewer colorectal lung metastases with a maximum tumor size of 3 cm and absence of extrapulmonary lesions. Lung RF ablation candidates who underwent pretreatment PET/CT studies were included. The incidence of detection of unexpected recurrent lesions on PET/CT was evaluated, along with its impact on subsequent treatments. Factors linked with the incidence of unexpected recurrent lesions were evaluated using univariate and multivariate analyses. RESULTS: Between October 2008 and June 2011, 60 patients were enrolled. Among the unexpected abnormal F-FDG accumulations found in 13 patients (21.7%), presence of extrapulmonary lesions was proved in 12 patients (20.0%, 12/60), prompting treatment strategy changes. One false-positive case was found (1.7%, 1/60). The sensitivity, specificity, and accuracy in detecting unexpected lesions by PET/CT were, respectively, 100, 97.9, and 98.3%. Elevation of the serum carcinoembryonic antigen level (>6.0 ng/ml) was the only significant factor linked with unexpected lesions in both univariate (P=0.02) and multivariate analyses (P=0.02). CONCLUSION: A PET/CT study should be performed in patients with colorectal lung metastasis before selecting them for lung RF ablation, especially when the carcinoembryonic antigen level is elevated.
Nuclear Medicine Communications 04/2013; · 1.40 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The objective of this study was to compare the diagnostic performance for detecting local tumor progression between FDG PET and CT in patients who received lung radiofrequency (RF) ablation for the treatment of malignant lung tumors.
A total of 469 FDG PET/CT studies were performed at 4 time points (3, 6, 9, 12 months) after lung RF ablation in 143 patients (87 male and 56 female patients) with 231 tumors. The SUVmax was calculated in treated tumors in each PET image. The percentage decrease (% decrease) in ablative zone size was evaluated in each CT image. The final response was judged based on follow-up findings and histology. Diagnostic performance of FDG PET and CT images was evaluated using receiver operating characteristic analysis.
Local tumor progression was identified in 37 patients (25.9%, 37/143) having 47 tumors (20.4%, 47/231) during the median follow-up of 24 months (range, 8-75 months). The area under the receiver operating characteristic curve of PET was higher than that of CT at all 4 time points (0.71 vs 0.55 at 3 months, 0.82 vs 0.60 at 6 months, 0.84 vs 0.66 at 9 months, and 0.92 vs 0.68 at 12 months), and its diagnostic performance was significant at each time point (P = 0.0010 at 3 months and P < 0.001 at 6, 9, and 12 months). However, the area under the receiver operating characteristic curve of CT was significant at 9 months (P = 0.040) and 12 months (P = 0.032).
FDG PET/CT is better able to assess local tumor progression at 3 and 6 months after lung RF ablation than CT alone.
Clinical nuclear medicine 04/2013; 38(4):e166-70. · 3.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We reviewed outcome for pulmonary metastases from malignant osteogenic and soft tissue sarcomas. From January 2001 to December 2010, 43 patients with pulmonary metastases from malignant osteogenic and soft tissue sarcomas were treated. Twenty-four were male and 19 were female. Age ranged 12~86(median 47.3)years. Operations were performed in 12 cases (group O), radiofrequency ablations were performed in 16 cases( group R), and both were performed in 13 cases( group OR). Overall 5-year survival rate was 24.5%.The 5-year survival was 50.2% for patients with a disease-free interval of more than 12 months and 6.1% for those with a disease-free interval of less than 12 months. There was significant difference in cases of bilateral pulmonary metastases between the group O and the other 2 groups. There was significant difference in the numbers of treated lesions between the group OR and the other 2 groups. There was no difference in overall survival among the 3 groups. These results might suggest that the hybrid therapy of operation and radiofrequency ablation improves the prognosis of patients with pulmonary metastases from malignant osteogenic and soft tissue sarcomas.
Kyobu geka. The Japanese journal of thoracic surgery 04/2013; 66(4):311-4.
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: To evaluate differences in the viscosity of a platinum iodized-oil suspension on the kind of platinum agent and temperature. MATERIALS AND METHODS: Viscosities of a 70 mg miriplatin and 3.5 ml iodized-oil suspension (MO suspension) and that of 100 mg cisplatin and 10 ml iodized-oil suspension (CO suspension) were evaluated at three temperatures: 25, 37, and 50 °C. Iodized-oil was used as the control. Each liquid was injected into a capillary tube and allowed to drip separately. The liquid transit time was measured, and the viscosity of each liquid was calculated at each temperature. RESULTS: The viscosity of each liquid decreased as the temperature increased: 43.3 ± 0.5, 39.2 ± 0.7, and 34.7 ± 0.6 mPa s for MO suspension, 41.3 ± 0.2, 36.9 ± 0.3, and 32.7 ± 0.9 mPa s for CO suspension, and 40.5 ± 0.2, 36.8 ± 0.2, and 33.8 ± 0.7 mPa s for iodized-oil at 25, 37, and 50 °C, respectively. The MO suspension group viscosity was significantly higher than that of the CO suspension group (p < 0.05) and the control (p < 0.05). Significant differences were found in viscosities among groups divided by temperature (25 °C-group vs. 37 °C-group, p < 0.05; 37 °C-group vs. 50 °C-group, p < 0.05). CONCLUSION: The viscosity of the platinum iodized-oil suspension can be adjusted by changing temperature.
Japanese journal of radiology 03/2013; · 0.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The purpose of this article is to retrospectively evaluate the frequency of and risk factors for complications after liver radiofrequency ablation (RFA).
This was a retrospective study of 656 patients (with 1755 liver tumors) who underwent 1500 CT fluoroscopy-guided liver RFA sessions. Of those patients, 501 had primary liver tumor and 155 had liver metastases. Mortality and treatment-related complications were documented. Complications were evaluated according to the Common Terminology Criteria for Adverse Events (version 4.0). Major complications were defined as grade 3 or higher adverse events. Factors affecting frequent complications with a frequency of 1% or more were detected using multivariate analysis.
Two deaths (0.1% [2/1500]) occurred. One patient died of liver failure subsequent to hemorrhage, and the other died of liver failure. The major complication rate was 2.8% (42/1500). The most frequent major complication was hemorrhage (1.1% [16/1500]). The absence of arterial embolization before RFA (p < 0.01), low hemoglobin level (p < 0.04), and elevated serum creatinine level (p < 0.04) were identified as significant risk factors for major hemorrhage. The minor complication rate was 17.1% (257/1500). Pneumothorax (7.7% [116/1500]) was the most frequent minor complication, followed by hemorrhage (7.0% [105/1500]). A transthoracic approach (p < 0.01) and subphrenic tumor location (p < 0.01) were significant risk factors for pneumothorax, and the use of a cluster needle (p < 0.02) and multiple tumors (p < 0.01) were significant risk factors for minor hemorrhage.
CT fluoroscopy-guided RFA is a safe procedure with an acceptably low rate of major complications for liver tumor treatment. Factors identified in this study will help to stratify high-risk patients.
American Journal of Roentgenology 03/2013; 200(3):658-64. · 2.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: To report 10-year outcomes of treating hepatocellular carcinomas (HCCs) by combination therapy of chemoembolization and radiofrequency (RF) ablation. MATERIALS AND METHODS: Combination therapy was administered in 277 patients with 382 treatment-naïve HCCs. Therapeutic effects, safety, survival rate, and prognostic factors were evaluated. RESULTS: Tumor enhancement disappeared after 466 RF sessions in all tumors, resulting in a complete response rate of 100% (277 of 277) based on modified Response Evaluation Criteria In Solid Tumors. Local tumor progression developed in 15 patients (5.4%; 15 of 277) during the mean follow-up of 44.9 months±29.1 (range, 6.0-134.4 mo). Overall and recurrence-free survival rates were 56.3% (95% confidence interval [CI], 52.5%-60.2%) and 22.5% (95% CI, 19.3%-25.6%) at 5 years and 23.5% (95% CI, 17.7%-29.2%) and 9.3% (95% CI, 6.3%-12.4%) at 10 years. The Child-Pugh class was the only significant prognostic factor detected in both the univariate (P<.001) and the multivariate analyses (hazard ratio, 3.8; 95% CI, 2.5-5.6; P<.001). The 5-year and 10-year overall survival rates were 66.4% (95% CI, 62.0%-70.8%) and 30.6% (95% CI, 23.3%-37.9%) in 210 Child-Pugh class A patients. In addition to the Child-Pugh class, the maximum tumor diameter (≤3 cm vs>3 cm) and the tumor number (single vs multiple) were significant independent factors affecting recurrence-free survival. No death was related to the combination therapy. The major complication rate was 3.2% (15 of 466). CONCLUSIONS: RF ablation combined with chemoembolization is a safe and useful therapeutic option for treating HCCs. Prognostic factors detected in this study help to stratify patients who benefit from this combination therapy.
Journal of vascular and interventional radiology: JVIR 02/2013; · 1.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: To improve the selection of patients for percutaneous abscess drainage (PAD) to treat postoperative intra-abdominal abscess after gastrointestinal surgery, we investigated the factors predictive of outcome. METHODS: Of 143 consecutive patients with symptomatic postoperative intra-abdominal abscess after a gastrointestinal tract resection, 104 who underwent image-guided PAD as the initial treatment were reviewed. We assessed the possible associations between successful PAD and patient-, abscess-, surgical-, and drainage-related variables, and investigated the success rates of PAD for patients with vs. those without the factors related to successful outcome. RESULTS: Based on monitoring for 1 year after PAD, the success rate of this procedure was 85.6 % (89/104). Multivariate analysis revealed that the interval between surgery and the onset of abscess (p = 0.0234) and a single abscess (p = 0.0038) were independently associated with a successful outcome. Single late-onset abscess resolved completely within 10 weeks in 91.4 % of these patients. CONCLUSIONS: Despite new strategies aimed at preventing surgical site infection, PAD remains an important factor in the postoperative management of gastrointestinal surgery in Japan. Initial recognition of the day of onset and the number of abscesses are important prognostic factors.
Surgery Today 02/2013; · 1.22 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study evaluated the safety, feasibility, and clinical utility of hyaluronic acid gel injection to separate the gastrointestinal tract from the tumor during liver radiofrequency ablation (RFA). Eleven patients with liver tumors measuring 0.9-3.5 cm (mean ± standard deviation, 2.1 ± 0.8 cm) that were adjacent to the gastrointestinal tracts received RFA after the mixture of hyaluronic acid gel and contrast material (volume, 26.4 ± 14.5 mL; range, 10-60 mL) was injected between the tumor and the gastrointestinal tract under computed tomographic-fluoroscopic guidance. Each tumor was separated from the gastrointestinal tract by 1.0-1.5 cm (distance, 1.2 ± 0.2 cm) after injection of hyaluronic acid gel, and subsequent RFA was performed without any complications in all patients. Although tumor enhancement disappeared in all patients, local tumor progression was found in a patient (9.1 %, 1 of 11) during the follow-up of 5.5 ± 3.2 months (range, 0.4-9.9 months). In conclusion, hyaluronic acid gel injection is a safe and useful technique to avoid thermal injury of the adjacent gastrointestinal tract during liver RFA.
CardioVascular and Interventional Radiology 01/2013; · 2.09 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: To evaluate the feasibility, safety, and clinical outcomes of radiofrequency (RF) ablation for the treatment of liver metastases from gastrointestinal stromal tumor (GIST). MATERIALS AND METHODS: Seven consecutive patients with 21 GIST liver metastases received RF ablation under computed tomographic (CT) fluoroscopic guidance. Liver metastases were solitary in two patients and multiple in five patients, with a mean maximum tumor diameter of 2.2 cm±1.1 (range, 1.2-4.2 cm). In addition to feasibility and safety, local tumor progression and overall and GIST-related survival associated with RF ablation were assessed. RESULTS: All liver metastases were treated in 12 RF sessions, after which contrast-enhanced CT showed disappearance of tumor enhancement. No RF procedure-related complications occurred. Local tumor progression developed in one tumor (4.8%) during the mean follow-up period of 30.6 months±27.5 (range, 5.9-76.4 mo). New liver metastasis in untreated liver and lung metastasis developed in one patient each. One patient died of subarachnoid hemorrhage 5.9 months after RF ablation, but no GIST-related deaths occurred. The respective overall and GIST-related survival rates were 85.7% (95% confidence interval, 33.6%-97.8%) and 100% at 1, 3, and 5 years. CONCLUSIONS: RF ablation is a feasible, safe, and useful therapeutic option for the treatment for GIST liver metastases.
Journal of vascular and interventional radiology: JVIR 01/2013; · 1.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Purpose:To prospectively evaluate the safety and effectiveness of radiofrequency ablation with a multiple-electrode switching system for the treatment of renal cell carcinoma (RCC).Materials and Methods:From November 2009 to December 2010, 33 patients (mean age, 70.7 years; range, 44-86 years) with histologically proved RCCs-including 24 men (mean age, 69.5 years [range, 44-86 years]) and nine women (mean age, 74.1 years [range, 64-83 years])-were enrolled in this phase II study. The institutional review board approved the study after patients provided written informed consent. The mean maximum tumor diameter was 2.9 cm ± 1.0 (standard deviation) (range, 1.5-5.0 cm). Radiofrequency ablation was conducted with a multiple-electrode switching system. The primary endpoint was evaluated with the Common Terminology Criteria for Adverse Events. Secondary endpoints were changes in renal function, technique effectiveness, local tumor progression, and survival. Changes in renal function were evaluated by using the Mann-Whitney U test.Results:No severe adverse events occurred, but three of 33 patients (9%) had grade 2 adverse events. Although the mean glomerular filtration rate at 1 year after radiofrequency ablation was similar to the baseline value in 26 patients with bilateral kidneys (P = .14), it was decreased significantly in six patients with a single kidney (P = .03). Tumor enhancement disappeared after a single radiofrequency session in 31 patients and after two radiofrequency sessions in the other two patients (rates of primary and secondary technique effectiveness, 94% [31 of 33] and 100% [33 of 33], respectively). No local tumor progression was found during the mean follow-up of 20.0 months (range, 11.6-27.6 months). The respective 1-year overall and RCC-related survival rates were 97% (95% confidence interval: 91%, 100%) and 100%.Conclusion:Radiofrequency ablation with a multiple-electrode switching system is safe and effective for treatment of RCCs. However, further study is warranted to determine whether this technology is superior to other previously described methods.© RSNA, 2013.
Radiology 01/2013; · 5.73 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the clinical utility of radiofrequency (RF) ablation combined with chemoembolization in treatment of hepatocellular carcinoma (HCC) located in the caudate lobe.
Between September 2000 and October 2011, 20 consecutive patients with single HCC measuring≤5 cm were treated with combination therapy of chemoembolization and RF ablation. Technical success was defined as completion of a planned electrode placement and ablation protocol. The effectiveness of the technique was defined as disappearance of tumor enhancement with an ablative margin of≥5 mm. Technical success, technique effectiveness, local tumor progression, overall and recurrence-free survival, and complications were evaluated.
RF electrodes were placed in planned sites of each tumor, and ablation was complete in all patients (technical success rate 100%). Tumor enhancement disappeared with sufficient ablative margins after 20 RF sessions in all patients (technique effectiveness rate 100%). Major and minor complication rates were 10.0% and 15.0%. Local tumor progression was found in 2 of 20 patients (10.0%) with local tumor progression rates of 6.3% at 1 year and 13.5% at 3 years and 5 years. Six patients died during the follow-up period (mean, 40.0 months; range, 2.0-110.5 months). Overall and recurrence-free survival rates were 94.4% and 70.8% at 1 year, 86.6% and 36.9% at 3 years, and 67.5% and 45.5% at 5 years.
RF ablation combined with chemoembolization is a safe and useful therapeutic option to treat HCCs located in the caudate lobe.
Journal of vascular and interventional radiology: JVIR 12/2012; 23(12):1622-8. · 1.81 Impact Factor
-
Tetsuya Beppu,
Kazushi Sugimoto,
Katsuya Shiraki,
Masahiko Tameda,
Yuji Inagaki,
Suguru Ogura,
Chika Kasai,
Satoko Kusagawa,
Keiichiro Nojiri,
Misao Yoneda, [......],
Yoshiyuki Takei,
Masashi Fujimori,
Takaaki Hasegawa,
Takashi Yamanaka,
Junichi Uraki,
Masataka Kashima,
Haruyuki Takaki,
Atsuhiro Nakatsuka, Koichiro Yamakado,
Kan Takeda
[show abstract]
[hide abstract]
ABSTRACT: We evaluated the clinical efficacy of transarterial infusion chemotherapy using a cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma (HCC).
Fifty-seven patients with advanced HCC, with no indications for surgical resection or local ablative therapy, such as percutaneous ethanol injection and radiofrequency ablation, were enrolled in this retrospective study.
Twelve patients were treated with cisplatin-alone at a dose of 65 mg/m(2) by infusion into the artery. Forty-two patients were treated with the same dose of cisplatin suspended in 1-10 ml of lipiodol (C/LPD). Cumulative survival rates in the cisplatin-treated group were 46.2% at one year, and 18.5% at two years, whereas these in the C/LPD group were 81.6% and 44.4%, respectively, with a significant difference between the two groups (p<0.01). In the cisplatin-treated group (n=13), no (0%) patients had a complete response (CR), two (15%) a partial response (PR), three (23%) no change (NC), and eight (62%) progressive disease (PD). In the C/LPD group (n=44), four (9%) patients had CR, 16 (35%) PR, 12 (26%) NC, and 12 (26%) PD. CR and PR were seen in 15% of the cisplatin-treated group and in 44% of the C/LPD group. C/LPD was significantly more effective than cisplatin-alone (p=0.039). Some patients showed tumor response to C/LPD after intra-arterial infusion of low-dose 5-fluorouracil.
C/LPD produced superior effects compared to cisplatin-alone for unresectable HCC, causing no major side-effects, and increasing the survival rate.
Anticancer research 11/2012; 32(11):4923-30. · 1.73 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To determine prognostic factors in patients with colorectal liver metastases who were not surgical candidates and received liver radiofrequency (RF) ablation.
RF ablation was done for 141 colorectal liver metastases in 84 patients. There were 63 (75.0 %, 63/84) males and 21 (25.0 %, 21/84) females, with a mean age of 64.6 ± 10.3. The mean maximum tumor diameter was 2.3 ± 1.4 cm (range 0.5-9.0 cm). Extrahepatic metastases were associated at the time of liver RF ablation in 23 patients (27.4 %, 23/84), and 12 (14.3 %, 12/84) had lung metastases considered controllable by planned lung RF ablation. Prognostic factors were evaluated by univariate and multivariate analyses.
There was no procedure-related mortality. The 1-, 3-, and 5-year overall survival rates were 90.6 % (95 %CI, 83.9-97.2 %), 44.9 % (95 %CI, 31.8-57.9 %), and 20.8 % (95 %CI, 7.3-34.3 %), respectively, with a median survival of 34.9 months. The univariate analysis showed that tumor diameter larger than 3 cm, tumor multiplicity, uncontrollable extrahepatic disease, and previous chemotherapy history were significantly worse prognostic factors. The former three factors remained significant for worse prognosis in the multivariate Cox model. Extrahepatic disease was not a prognostic factor when it could be controlled.
Tumor size and number, and uncontrollable extrahepatic metastases were significant prognostic factors.
Japanese journal of radiology 06/2012; 30(7):567-74. · 0.65 Impact Factor
-
Koichiro Yamakado,
Shiro Miyayama,
Shozo Hirota,
Kimiyoshi Mizunuma,
Kenji Nakamura,
Yoshitaka Inaba,
Akihiro Maeda,
Kunihiro Matsuo,
Norifumi Nishida,
Takeshi Aramaki,
Hiroshi Anai,
Shinichi Koura,
Shigeo Oikawa,
Ken Watanabe,
Taku Yasumoto,
Kinya Furuichi,
Masato Yamaguchi
[show abstract]
[hide abstract]
ABSTRACT: To evaluate retrospectively whether technical factors of hepatic arterial embolization affect the prognosis of patients with hepatocellular carcinoma (HCC).
Inclusion criteria of this study were the following: (1) patients received embolization as the initial treatment during 2003-2004, (2) Child A or B liver profile, (3) five or fewer HCCs with maximum diameter of 7 cm or smaller, and (4) no extrahepatic metastasis. Patient data were gathered from 43 centers. Prognostic factors were evaluated using univariate and multivariate analyses.
Eight hundred fifteen patients were enrolled. The 1-, 3-, 5-, and 7-year overall survival rates were 92.0 % (95 % CI 90.1-93.9), 62.9 % (95 % CI 59.3-66.6), 39.0 % (95 % CI 35.1-43.0), and 26.7 % (95 % CI 22.6-30.8) in all patients. Univariate analysis showed a Child-Pugh class-A, alpha-fetoprotein level lower than 100 ng/ml, tumor size of 3 cm or smaller, tumor number of 3 or fewer, one-lobe tumor distribution, nodular tumor type, within the Milan criteria, stage I or II, no portal venous invasion, use of iodized oil, and selective embolization were significantly better prognostic factors. In the multivariate Cox model, the benefit to survival of selective embolization remained significant (hazard ratio 0.68; 95 % CI 0.48-0.97; p = 0.033).
Selective embolization contributes to survival in patients with HCCs.
Japanese journal of radiology 05/2012; 30(7):560-6. · 0.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We retrospectively evaluated whether combined use of chemoembolization expands ablative zone sizes created by radiofrequency (RF) ablation in patients with small hepatocellular carcinomas (HCCs).
Fifty-seven patients treated with single RF ablation for solitary HCC measuring ≤2 cm were assessed. RF ablation alone was done in nine patients and in 48 patients following chemoembolization, with an interval of 0 days in 6, 1-14 days in 27, 15-28 days in 6, and ≥4 weeks in 9. Ablative zone sizes, disappearance of tumor enhancement, and creation of sufficient ablative margins (>5 mm) were evaluated on contrast-enhanced computed tomography (CT) images.
Both mean long-axis (4.2-4.7 vs. 3.6 ± 0.4 cm, p < 0.04) and short-axis (3.3-3.8 vs. 2.3 ± 0.5 cm, p < 0.03) diameters were expanded significantly when RF ablation was done until 4 weeks after chemoembolization than with RF ablation alone. Tumor enhancement disappeared in all patients. Frequency of achieving sufficient ablative margins was significantly higher when RF ablation was done until 4 weeks after chemoembolization than with RF ablation alone (74.0-83.3 vs. 22.2 %, p < 0.05).
Ablative zones created by RF ablation with chemoembolization become larger than RF ablation alone, leading to secure ablative margins.
Japanese journal of radiology 05/2012; 30(7):553-9. · 0.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the clinical utility of a new method with dynamic single photon emission computed tomography (SPECT) and scatter
and attenuation compensation to estimate both total and regional liver function quantitatively. Five controls, 20 patients
with chronic liver disease, and 2 patients with Budd-Chiari syndrome were studied. Dynamic liver SPECT data were acquired
during 20 minutes after injection of Technetium (Tc)-99m diethylenetriaminepentaacetic acid (DTPA) galactosyl human serum
albumin (GSA) with scatter and attenuation compensation. The binding rate constant of Tc-99m GSA, (Ku) was derived quantitatively from the Patlak plot based on kinetic models for GSA receptor binding. The mean Ku was obtained by dividing the Ku value (total Ku) by the liver volume. Both total and mean Ku were significantly lower in patients with chronic liver disease than in controls (302±112 vs. 523±78ml/min; p<0.001, 0.26±0.11
vs. 0.43±0.03 ml/min/cm3; p<0.001). In the patient group, both total and mean Ku were significantly correlated with the results of conventional liver function tests and the histological severity of chronic
liver disease. In 2 patients with Budd-Chiari syndrome, the mean Ku was lower in the right lobe, where the hepatic veins were occluded, than in the left lobe, where draining veins were patent.
In conclusion, this method is a reliable diagnostic technique for estimating total and regional liver function.
Annals of Nuclear Medicine 04/2012; 15(3):191-198. · 1.50 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: To evaluate the incidence and cause of hypertension prospectively during adrenal radiofrequency ablation (RFA). METHODS: For this study, approved by our institutional review board, written informed consent was obtained from all patients. Patients who received RFA for adrenal tumors (adrenal ablation) and other abdominal tumors (nonadrenal ablation) were included in this prospective study. Blood pressure was monitored during RFA. Serum adrenal hormone levels including epinephrine, norepinephrine, dopamine, and cortisol levels were measured before and during RFA. The respective incidences of procedural hypertension (systolic blood pressure >200 mmHg) of the two patient groups were compared. Factors correlating with procedural systolic blood pressure were evaluated by regression analysis. RESULTS: Nine patients underwent adrenal RFA and another 9 patients liver (n = 5) and renal (n = 4) RFA. Asymptomatic procedural hypertension that returned to the baseline by injecting calcium blocker was found in 7 (38.9%) of 18 patients. The incidence of procedural hypertension was significantly higher in the adrenal ablation group (66.7%, 6/9) than in the nonadrenal ablation group (11.1%, 1/9, P < 0.0498). Procedural systolic blood pressure was significantly correlated with serum epinephrine (R (2) = 0.68, P < 0.0001) and norepinephrine (R (2) = 0.72, P < 0.0001) levels during RFA. The other adrenal hormones did not show correlation with procedural systolic blood pressure. CONCLUSION: Hypertension occurs frequently during adrenal RFA because of the release of catecholamine.
CardioVascular and Interventional Radiology 01/2012; · 2.09 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: BACKGROUND: We aimed to evaluate therapeutic outcomes of radiofrequency (RF) ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas (HCCs) invisible on ultrasonographic (US) images. MATERIALS AND METHODS: Informed consent was waived for this retrospective study approved by our institutional review board. Sixty-seven consecutive patients with 150 HCCs (mean diameter 1.3 ± 0.6 cm; range 0.5-4.2 cm) received 90 RF sessions following intra-arterial iodized-oil injection. Each patient had at least one HCC invisible on US images. Computed tomography (CT) fluoroscopy-guided RF ablation was performed within 1 week after the injection of iodized oil from feeding arteries of each tumor. Technical success was defined as a planned electrode placement and completion of ablation protocol. Technical success, complications, changes in liver function, local tumor progression, and survival were evaluated. RESULTS: All HCCs became visible on CT fluoroscopy after iodized-oil injection, and RF ablation was technically successful in all sessions (technical success rate, 100%, 90/90). Major complications occurred in 6 RF sessions (6.7%, 6/90), including hemorrhage (2.2%, 2/90), portal thrombosis (2.2%, 2/90), and pneumothorax (2.2%, 2/90). No significant deterioration in Child-Pugh score was found. The mean follow-up period was 23.2 ± 18.0 months. The cumulative local tumor progression rates and overall survival rates were, respectively, 3.9 and 82.7% at 1 year, 5.3 and 45.3% at 3 years, and 5.3 and 26.4% at 5 years. CONCLUSION: CT fluoroscopy-guided RF ablation following intra-arterial iodized-oil injection is a feasible, safe, and useful therapeutic option for HCCs invisible on US images.
International Journal of Clinical Oncology 10/2011; · 1.41 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study retrospectively evaluates complications after lung radiofrequency ablation (RFA).
Complications were assessed for each RFA session in 420 consecutive patients with 1403 lung tumors who underwent 1000 RFA sessions with a cool-tip RFA system. A major complication was defined as a grade 3 or 4 adverse event. Risk factors affecting frequent major complications that occurred with an incidence of 1% or more were detected using multivariate analysis.
Four deaths (0.4% [4/1000]) related to RFA procedures occurred. Three patients died of interstitial pneumonia. The other patient died of hemothorax. The major complication rate was 9.8% (98/1000). Frequent major complications were aseptic pleuritis (2.3% [23/1000]), pneumonia (1.8% [18/1000]), lung abscess (1.6% [16/1000]), bleeding requiring blood transfusion (1.6% [16/1000]), pneumothorax requiring pleural sclerosis (1.6% [16/1000]), followed by bronchopleural fistula (0.4% [4/1000]), brachial nerve injury (0.3% [3/1000]), tumor seeding (0.1% [1/1000]), and diaphragm injury (0.1% [1/1000]). Puncture number (p < 0.02) and previous systemic chemotherapy (p < 0.05) were significant risk factors for aseptic pleuritis. Previous external beam radiotherapy (p < 0.001) and age (p < 0.02) were significant risk factors for pneumonia, as were emphysema (p < 0.02) for lung abscess, and serum platelet count (p < 0.002) and tumor size (p < 0.02) for bleeding. Emphysema (p < 0.02) was a significant risk factor for pneumothorax requiring pleural sclerosis.
Lung RFA is a relatively safe procedure, but it can be fatal. Risk factors found in this study will help to stratify high-risk patients.
American Journal of Roentgenology 10/2011; 197(4):W576-80. · 2.78 Impact Factor
